Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation

Authors

  • Rickard Ljung National Board of Health and Welfare, Stockholm, Sweden;Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Equity and Health Policy, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
  • Mats Talbäck National Board of Health and Welfare, Stockholm, Sweden
  • Bengt Haglund National Board of Health and Welfare, Stockholm, Sweden
  • Junmei Miao Jonasson Division of Clinical Cancer Epidemiology, Department of Oncology, The Sahlgrenska Academy, Onkologiskt Centrum, Gothenburg, Sweden;Division of Clinical Cancer Epidemiology, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; National Diabetes Register, Register Center, Västra Götaland Region, Sweden
  • Soffia Gudbjörnsdòttir Diabetes Centre, Sahlgrenska University Hospital, Gothenburg, Sweden;Nordic School of Public Health, Gothenburg, Sweden; National Diabetes Register, Register Center, Västra Götaland Region, Sweden
  • Gunnar Steineck Division of Clinical Cancer Epidemiology, Department of Oncology, The Sahlgrenska Academy, Onkologiskt Centrum, Gothenburg, Sweden

DOI:

https://doi.org/10.3109/0284186X.2011.624118

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2012-03-01

How to Cite

Ljung, R., Talbäck, M., Haglund, B., Miao Jonasson, J., Gudbjörnsdòttir, S., & Steineck, G. (2012). Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation. Acta Oncologica, 51(3), 400–402. https://doi.org/10.3109/0284186X.2011.624118

Issue

Vol. 51 No. 3 (2012): Acta Oncologica

Section

Articles